• Something wrong with this record ?

Crosstalk between autophagy inhibitors and endosome-related secretory pathways: a challenge for autophagy-based treatment of solid cancers

M. Raudenska, J. Balvan, M. Masarik

. 2021 ; 20 (1) : 140. [pub] 20211027

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

Persistent link   https://www.medvik.cz/link/bmc22012061

Grant support
21-06873S Grantová Agentura České Republiky
NU20J-08-00018 Agentura Pro Zdravotnický Výzkum České Republiky

Autophagy is best known for its role in organelle and protein turnover, cell quality control, and metabolism. The autophagic machinery has, however, also adapted to enable protein trafficking and unconventional secretory pathways so that organelles (such as autophagosomes and multivesicular bodies) delivering cargo to lysosomes for degradation can change their mission from fusion with lysosomes to fusion with the plasma membrane, followed by secretion of the cargo from the cell. Some factors with key signalling functions do not enter the conventional secretory pathway but can be secreted in an autophagy-mediated manner.Positive clinical results of some autophagy inhibitors are encouraging. Nevertheless, it is becoming clear that autophagy inhibition, even within the same cancer type, can affect cancer progression differently. Even next-generation inhibitors of autophagy can have significant non-specific effects, such as impacts on endosome-related secretory pathways and secretion of extracellular vesicles (EVs). Many studies suggest that cancer cells release higher amounts of EVs compared to non-malignant cells, which makes the effect of autophagy inhibitors on EVs secretion highly important and attractive for anticancer therapy. In this review article, we discuss how different inhibitors of autophagy may influence the secretion of EVs and summarize the non-specific effects of autophagy inhibitors with a focus on endosome-related secretory pathways. Modulation of autophagy significantly impacts not only the quantity of EVs but also their content, which can have a deep impact on the resulting pro-tumourigenic or anticancer effect of autophagy inhibitors used in the antineoplastic treatment of solid cancers.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012061
003      
CZ-PrNML
005      
20220506130422.0
007      
ta
008      
220425s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12943-021-01423-6 $2 doi
035    __
$a (PubMed)34706732
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Raudenska, Martina $u Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00, Brno, Czech Republic $u Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, CZ-613 00, Brno, Czech Republic $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00, Brno, Czech Republic
245    10
$a Crosstalk between autophagy inhibitors and endosome-related secretory pathways: a challenge for autophagy-based treatment of solid cancers / $c M. Raudenska, J. Balvan, M. Masarik
520    9_
$a Autophagy is best known for its role in organelle and protein turnover, cell quality control, and metabolism. The autophagic machinery has, however, also adapted to enable protein trafficking and unconventional secretory pathways so that organelles (such as autophagosomes and multivesicular bodies) delivering cargo to lysosomes for degradation can change their mission from fusion with lysosomes to fusion with the plasma membrane, followed by secretion of the cargo from the cell. Some factors with key signalling functions do not enter the conventional secretory pathway but can be secreted in an autophagy-mediated manner.Positive clinical results of some autophagy inhibitors are encouraging. Nevertheless, it is becoming clear that autophagy inhibition, even within the same cancer type, can affect cancer progression differently. Even next-generation inhibitors of autophagy can have significant non-specific effects, such as impacts on endosome-related secretory pathways and secretion of extracellular vesicles (EVs). Many studies suggest that cancer cells release higher amounts of EVs compared to non-malignant cells, which makes the effect of autophagy inhibitors on EVs secretion highly important and attractive for anticancer therapy. In this review article, we discuss how different inhibitors of autophagy may influence the secretion of EVs and summarize the non-specific effects of autophagy inhibitors with a focus on endosome-related secretory pathways. Modulation of autophagy significantly impacts not only the quantity of EVs but also their content, which can have a deep impact on the resulting pro-tumourigenic or anticancer effect of autophagy inhibitors used in the antineoplastic treatment of solid cancers.
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x farmakologie $x terapeutické užití $7 D000970
650    _2
$a autofagozomy $x metabolismus $7 D000071182
650    _2
$a autofagie $x účinky léků $7 D001343
650    _2
$a progrese nemoci $7 D018450
650    _2
$a endocytóza $x účinky léků $7 D004705
650    _2
$a endozomy $x metabolismus $7 D011992
650    _2
$a exozómy $x metabolismus $7 D055354
650    _2
$a lidé $7 D006801
650    12
$a cílená molekulární terapie $7 D058990
650    _2
$a nádory $x farmakoterapie $x etiologie $x metabolismus $7 D009369
650    _2
$a proteolýza $7 D059748
650    _2
$a sekreční dráha $x účinky léků $7 D055571
650    _2
$a signální transdukce $x účinky léků $7 D015398
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Balvan, Jan $u Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00, Brno, Czech Republic $u Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, CZ-613 00, Brno, Czech Republic $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00, Brno, Czech Republic
700    1_
$a Masarik, Michal $u Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00, Brno, Czech Republic. masarik@med.muni.cz $u Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, CZ-613 00, Brno, Czech Republic. masarik@med.muni.cz $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00, Brno, Czech Republic. masarik@med.muni.cz $u BIOCEV, First Faculty of Medicine, Charles University, Prumyslova 595, CZ-252 50, Vestec, Czech Republic. masarik@med.muni.cz $u Center for Advanced Functional Nanorobots, Department of Inorganic Chemistry, Faculty of Chemical Technology, University of Chemistry and Technology in Prague, Technická 5, CZ-166 28, Prague, Czech Republic. masarik@med.muni.cz $1 https://orcid.org/0000000311727195 $7 xx0104244
773    0_
$w MED00008245 $t Molecular cancer $x 1476-4598 $g Roč. 20, č. 1 (2021), s. 140
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34706732 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130415 $b ABA008
999    __
$a ok $b bmc $g 1789592 $s 1163262
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 20 $c 1 $d 140 $e 20211027 $i 1476-4598 $m Molecular cancer $n Mol Cancer $x MED00008245
GRA    __
$a 21-06873S $p Grantová Agentura České Republiky
GRA    __
$a NU20J-08-00018 $p Agentura Pro Zdravotnický Výzkum České Republiky
LZP    __
$a Pubmed-20220425

Find record

Citation metrics

Archiving options